SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
PLX Analysis & Videos »
PLX: Bull or Bear?
rated strong buy
PLX
|
|
|
+8.29%
in
83 days
Yesterday, Protalix BioTherapeutics, Inc. ( PLX - Snapshot Report ) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to prGCD for the treatment of Gaucher disease, an enzyme disorder that can cause liver and neurological problems
|
FDA Calendar Updates: Genzyme FDA Woes Benefit Protalix, Shire
PLX
|
|
|
+13.69%
in
126 days
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 293 entries as of 7/31/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial results. ...
|
FDA Calendar: 2H09 Binary Event Trades
PLX
|
|
|
+10.57%
in
5 days
(closed on 07/31/09)
<> Below is a selection of companies included in the BioMedReports.com FDA Calendar database of 281 entries as of 7/26/09 with expected binary event catalysts through year-end. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the ...
|
BioMedReports: FDA Calendar Updates
PLX
|
|
|
+27.82%
in
20 days
(closed on 07/26/09)
<> <font> Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 240 entries as of 7/6/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial results...
|
Bullish on PLX ...
PLX
|
|
|
+290.69%
in
247 days
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its principal product candidate, prGCD, is a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which has approval to commence phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in human...
|
People Bullish on PLX
People Bearish on PLX
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About Protalix BioTherapeutics Inc
- Answers.com
